864 Efficacy of Vedolizumab Induction Therapy in Patients With Crohn's Disease Who Have Experienced Tumor Necrosis Factor Antagonist Failure or Are Tumor Necrosis Factor Antagonist Naive

Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Irving H. Fox(Takeda (United States)), William Sandborn, Jing Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Paul Rutgeerts(KU Leuven), Brihad Abhyankar(Takeda (United Kingdom))
Gastroenterology
May 1, 2014
10.1016/s0016-5085(14)60531-x
Cited by 1

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k